Breztri Aerosphere Now Available in the US for Asthma
AstraZeneca's triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
AstraZeneca's triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
A collaboration between Jiva.ai and Aevice Health has developed a predictive model that identifies potential asthma exacerbations up to 72 hours in advance.
New data shows that patient visits and lung function tests for cystic fibrosis have not returned to 2019 levels despite new treatments and telehealth options.
Researchers suggest delivering vitamin D directly to the lungs could bypass the limitations of oral supplements in treating COPD and asthma.
ENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.
New research suggests cystic fibrosis transmembrane conductance regulator (CFTR) modulators may provide mental health benefits for pediatric patients and their caregivers early in treatment.
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
New research suggests that microplastic particles can bind to allergens and carry them deeper into the respiratory system.
An imaging study reveals how gene mutations impair airway clearance and lead to primary ciliary dyskinesia (PCD).